Please login to the form below

Not currently logged in
Email:
Password:

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

well as Biogen’s Eloctate, Bayer’s Kovaltry and CSLBehring’s Afstyla.

Latest news

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics